It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Kcnq1 overlapping transcript 1 (kcnq1ot1), an imprinted antisense lncRNA in the kcnq1 locus, acts as a potential contributor to cardiovascular disease, but its role in atherosclerosis remains unknown. The aim of this study was to explore the effects of kcnq1ot1 on atherogenesis and the underlying mechanism. Our results showed that kcnq1ot1 expression was significantly increased in mouse aorta with atherosclerosis and lipid-loaded macrophages. Lentivirus-mediated kcnq1ot1 overexpression markedly increased atherosclerotic plaque area and decreased plasma HDL-C levels and RCT efficiency in apoE−/− mice fed a Western diet. Upregulation of kcnq1ot1 also reduced the expression of miR-452-3p and ABCA1 but increased HDAC3 levels in mouse aorta and THP-1 macrophages. Accordingly, kcnq1ot1 overexpression inhibited cholesterol efflux and promoted lipid accumulation in THP-1 macrophages. In contrast, kcnq1ot1 knockdown protected against atherosclerosis in apoE−/− mice and suppressed lipid accumulation in THP-1 macrophages. Mechanistically, kcnq1ot1 enhanced HDAC3 expression by competitively binding to miR-452-3p, thereby inhibiting ABCA1 expression and subsequent cholesterol efflux. Taken together, these findings suggest that kcnq1ot1 promotes macrophage lipid accumulation and accelerates the development of atherosclerosis through the miR-452-3p/HDAC3/ABCA1 pathway.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, PR China (GRID:grid.443397.e) (ISNI:0000 0004 0368 7493)
2 The First Affiliated Hospital of Anhui Medical University, Department of Pathology, Hefei, PR China (GRID:grid.412679.f) (ISNI:0000 0004 1771 3402)
3 The Second Affiliated Hospital of Hainan Medical University, Department of Cardiology, Haikou, PR China (GRID:grid.443397.e) (ISNI:0000 0004 0368 7493)
4 The First School of Clinical Medicine, Anhui Medical University, Hefei, PR China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X)
5 Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, PR China (GRID:grid.443397.e) (ISNI:0000 0004 0368 7493); School of Basic Medical Sciences, Anhui Medical University, Department of Pathophysiology, Hefei, PR China (GRID:grid.186775.a) (ISNI:0000 0000 9490 772X)